Mind Medicine (MindMed) (NASDAQ:MNMD – Get Rating) and Grove (NASDAQ:GRVI – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.
Valuation & Earnings
This table compares Mind Medicine (MindMed) and Grove’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mind Medicine (MindMed)||N/A||N/A||-$93.04 million||-0.23||-3.06|
|Grove||$24.09 million||2.88||$2.98 million||N/A||N/A|
Institutional & Insider Ownership
12.4% of Mind Medicine (MindMed) shares are held by institutional investors. Comparatively, 1.8% of Grove shares are held by institutional investors. 2.1% of Mind Medicine (MindMed) shares are held by company insiders. Comparatively, 52.9% of Grove shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Mind Medicine (MindMed) and Grove’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mind Medicine (MindMed)||N/A||-62.00%||-57.05%|
This is a summary of recent ratings and recommmendations for Mind Medicine (MindMed) and Grove, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mind Medicine (MindMed)||0||0||3||0||3.00|
Mind Medicine (MindMed) currently has a consensus price target of 7.67, indicating a potential upside of 989.48%. Given Mind Medicine (MindMed)’s higher probable upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Grove.
Grove beats Mind Medicine (MindMed) on 6 of the 9 factors compared between the two stocks.
Mind Medicine (MindMed) Company Profile (Get Rating)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Grove Company Profile (Get Rating)
Grove, Inc., through its subsidiaries, engages in developing, producing, marketing, and selling raw materials, white label products, and end consumer products containing the industrial hemp plant extract, cannabidiol. The company serves consumer markets, including the botanical, beauty care, pet care, and functional food sectors. It also operates annual tradeshow related to the CBD industry in the United States. The company was incorporated in 2018 and is headquartered in Henderson, Nevada.
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.